Skip to content
  • Home
  • About us
  • Contact Us
Menu
  • Home
  • About us
  • Contact Us
  • General
  • Industry
  • Sports
  • Technology
  • Government & Politics
  • Health Maintenance
  • Press Releases
Menu
  • General
  • Industry
  • Sports
  • Technology
  • Government & Politics
  • Health Maintenance
  • Press Releases
Search
Close this search box.
  • Pakistan

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Newmont Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEM

February 7, 2025

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action

Read More

ROSEN, A LONGSTANDING LAW FIRM, Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – TGT

February 6, 2025

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action

Read More

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

February 5, 2025

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2

Read More

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

February 5, 2025

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2

Read More

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

February 5, 2025

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2

Read More

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

February 5, 2025

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2

Read More
Previous Page1 … Page147 Page148 Page149 Page150 Page151 … Page237 Next
  • Recent Post

Qatar Armed Forces Celebrate Graduation of 15th Military Science Diploma Cohort

June 24, 2026

Foreign Minister of Iceland Meets Ambassador of Qatar

June 24, 2026

QU Announces Minimum Admission Requirements for Undergraduate Programs Starting Fall 2027

June 24, 2026

One Palestinian Killed in Israeli Airstrike on Southern Gaza

June 24, 2026

Minister of State for International Cooperation Meets Pakistani Ambassador

June 24, 2026

Qatar Joins Virtual Event for Midterm Review of Doha Programme of Action Implementation

June 24, 2026

Join us as we navigate the ever-changing world of news, offering unique perspectives and meaningful stories that resonate with our readers. Whether you are interested in local news, international affairs, or market updates, Jazira Newswire is here to provide you with the information you need to make informed decisions. Trust us to bring you reliable and comprehensive coverage across a broad spectrum of subjects to deliver comprehensive coverage of global events. We are driven by a commitment to providing timely and accurate information on a wide range of topics. Our team is passionate about delivering news that matters, and keeping our readers informed and engaged.read more

Copyright © 2026 jaziranewswire.qa. All Rights Reserved.